PIK3CA and KRAS mutations are important predictors of resistance to therapy with EGFR-tyrosine kinase inhibitors in advanced non small cell lung cancer patients.

Research Area: Year: 2011
Type of Publication: Article
Authors:
  • Ludovini, V.
  • Bianconi, Fortunato
  • Pistola, L.
  • Chiari, R.
  • Minotti, V.
  • Colella, R.
  • Tofanetti, FR.
  • Siggillino, A.
  • Flacco, A.
  • Baldelli, E.
  • Giuffrida, D.
  • Iacono, D.
  • Mameli, MG.
  • Cavaliere, A.
  • Crinò., L.
Journal: JOURNAL OF THORACIC ONCOLOGY
BibTex: